Chronic Renal Failure, Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome
Conditions
Keywords
GHD, TS, CRF, SGA, ISS, PWS
Brief summary
The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).
Interventions
None listed
Sponsors
LG Chem
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* short stature children aged 2 years or more * children with GHD,TS, CRF, SGA or ISS * written informed consent from the person, person's parent or legal guardian
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety measure : adverse event | up to 2 years after epiphyseal closure |
Secondary
| Measure | Time frame |
|---|---|
| effectiveness measure : difference in target height and final height | up to 2 years after epiphyseal closure |
| effectiveness : difference in height velocity between Baseline and every year | up to 2 years after epiphyseal closure |
| effectiveness measure : difference in height SDS for CA between baseline and every 6 months | up to 2 years after epiphyseal closure |
Countries
South Korea
Contacts
Primary ContactYoungHwan Jang
Outcome results
None listed